A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial to Evaluate the Efficacy and Safety of a Vaccine, ASP0113, in Cytomegalovirus (CMV)-Seronegative Kidney Transplant Recipients Receiving an Organ From a CMV-Seropositive Donor
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 08 Nov 2019
Price : $35 *
At a glance
- Drugs VCL CB01 (Primary)
- Indications Cytomegalic inclusion disorders; Cytomegalovirus infections
- Focus Therapeutic Use
- Sponsors Astellas Pharma
- 09 May 2018 Results (n=149) assessing efficacy of ASP0113 compared to placebo in reducing the incidence of cytomegalovirus (CMV) viremia in CMV-seronegative subjects receiving a kidney from a CMV-seropositive donor, were published in the American Journal of Transplantation.
- 03 May 2017 Results presented at the 2017 American Transplant Congress.
- 19 Sep 2016 Primary endpoint has not been met. (Incidence of first cytomegalovirus (CMV) viremia), as reported by Astellas Pharma and Vical Media Release.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History